STOCK TITAN

Inspire Medical Systems, Inc. - INSP STOCK NEWS

Welcome to our dedicated page for Inspire Medical Systems news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical Systems stock.

Inspire Medical Systems, Inc. (INSP) is a pioneering medical technology company headquartered in Maple Grove, Minnesota. Specializing in the development and commercialization of innovative, minimally invasive solutions, Inspire focuses on providing effective treatments for patients with obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, is a revolutionary neurostimulation technology designed to safely and effectively treat moderate to severe OSA.

Inspire operates primarily across the United States and Europe, with the bulk of its revenue generated from the U.S. market. The company has seen significant growth, reporting a 65% increase in year-over-year revenue for the second quarter of 2023, reaching $151.1 million. This growth is attributed to increased utilization at existing sites, the addition of 72 new implanting centers, and 19 new U.S. sales territories.

In recent business highlights, Inspire has achieved several key milestones. These include the submission of the Inspire V neurostimulation PMA supplement application to the FDA and receiving two critical FDA approvals which expand the upper limit of the Apnea-Hypopnea Index (AHI) to 100 events per hour from 65 and raise the BMI warning in the labeling to 40 from 32. Additionally, Inspire received approval for its SleepSync™ physician programmer. These advancements are expected to enhance the company’s product offerings and market reach.

Financially, Inspire ended the second quarter of 2023 with a gross margin of 83.9% and operating expenses of $143.4 million, reflecting ongoing investments in U.S. sales expansion, direct-to-patient marketing, and product development. Despite a net loss of $12.0 million for the quarter, this marks an improvement from the $14.5 million loss in the same period the prior year.

Looking ahead, Inspire has increased its full-year 2023 revenue guidance to between $600 million and $610 million, reflecting a growth of 47% to 50% over the previous year. The company is committed to opening new medical centers and expanding its U.S. territories, anticipating sustained organic growth driven by its innovative therapies and strengthened leadership team.

For current updates and detailed information about Inspire Medical Systems, visit inspiresleep.com.

Rhea-AI Summary
INSP: Inspire Medical Systems, Inc. Appoints Carlton Weatherby as Chief Strategy Officer, focusing on innovative solutions for obstructive sleep apnea. Weatherby brings extensive experience from Medtronic, including leadership in medtech and strategic vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.95%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
Inspire Medical Systems, Inc. will participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series on May 22, 2023. The presentation will be accessible via a live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
conferences
-
Rhea-AI Summary
Inspire Medical Systems, Inc. (NYSE: INSP) reported an 84% increase in revenue for the first quarter of 2023, reaching $127.9 million. The company achieved a gross margin of 84.4% and activated 68 new centers in the U.S. during the quarter. They also created 17 new U.S. sales territories. Inspire received FDA approval for pediatric patients with Down syndrome and finalized countrywide reimbursement in Belgium. The company raised its full year 2023 revenue guidance to between $580 million to $590 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
none
-
Rhea-AI Summary

Inspire Medical Systems (NYSE: INSP) has announced its participation at the BofA Securities Health Care Conference 2023, scheduled for May 10, 2023, at 11:40 a.m. ET. The presentation will showcase its innovative solutions for obstructive sleep apnea, including the proprietary Inspire therapy, the only FDA-approved neurostimulation technology for treating moderate to severe cases. Interested parties can access the live webcast here. A replay will be available for two weeks on Inspire’s Investor website, which can be visited here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
Rhea-AI Summary

Inspire Medical Systems (NYSE: INSP) is set to release its first-quarter 2023 financial results on May 2, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time, where management will discuss results and recent business developments. Investors can access the call through the company’s Investor Relations webpage or via a direct link provided in the announcement. Inspire is known for its innovative Inspire therapy, the only FDA-approved neurostimulation treatment for moderate to severe obstructive sleep apnea, highlighting the company's focus on advancing medical technology in this specialized market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences earnings

FAQ

What is the current stock price of Inspire Medical Systems (INSP)?

The current stock price of Inspire Medical Systems (INSP) is $187.77 as of December 20, 2024.

What is the market cap of Inspire Medical Systems (INSP)?

The market cap of Inspire Medical Systems (INSP) is approximately 5.6B.

What is Inspire Medical Systems, Inc.?

Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA).

What is the Inspire system?

The Inspire system is a neurostimulation technology designed to provide a safe and effective treatment for moderate to severe obstructive sleep apnea (OSA).

What recent milestones has Inspire achieved?

Inspire recently submitted the Inspire V neurostimulation PMA supplement application to the FDA and received two critical FDA approvals, expanding the upper limit of the Apnea-Hypopnea Index (AHI) and raising the BMI warning in the labeling.

How did Inspire perform financially in the second quarter of 2023?

Inspire reported a 65% year-over-year revenue growth, reaching $151.1 million, with a gross margin of 83.9% and a net loss of $12.0 million.

What is the revenue guidance for Inspire in 2023?

Inspire has increased its full-year 2023 revenue guidance to between $600 million and $610 million, representing a growth of 47% to 50% over the previous year.

Where does Inspire generate most of its revenue?

The majority of Inspire's revenue is generated from the United States.

What are the key elements of Inspire's growth strategy?

Inspire's growth strategy includes expanding its U.S. sales organization, direct-to-patient marketing, product development, and activating new medical centers.

Who is the CEO of Inspire Medical Systems?

The CEO of Inspire Medical Systems is Tim Herbert.

What is the significance of the SleepSync™ physician programmer?

The SleepSync™ physician programmer is an approved device that enhances the management and programming capabilities for physicians treating OSA with the Inspire system.

How many new implanting centers did Inspire add in the second quarter of 2023?

Inspire added 72 new implanting centers in the second quarter of 2023.

Inspire Medical Systems, Inc.

NYSE:INSP

INSP Rankings

INSP Stock Data

5.56B
29.36M
1.95%
115.29%
7.48%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
GOLDEN VALLEY